Q-omics provides the consensus-scored GPER1 profile across patient tissues and cancer cell-line models. GPER1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GPER1 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, GPER1 RNA expression shows 13,274 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where GPER1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPER1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPER1 survival associations across molecular data types. GPER1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPER1 RNA expression–survival associations across cancer types. High GPER1 expression shows unfavorable associations in UVM and BLCA, but favorable associations in KIRC, ESCA, DLBC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GPER1 RNA expression.
This table summarizes GPER1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GPER1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPER1 shows lower tumor expression in KICH, COAD, LUSC, THCA and BLCA and higher tumor expression in HNSC. The KICH box plot shows higher GPER1 RNA expression in normal versus tumor tissue (log2 FC = −3.100, t-test p < 0.001).
This table shows molecular features associated with GPER1 in patient tissues and cancer cell lines. In patient samples, GPER1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GPER1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
